CagriSema // The Amylin Play
Novo Nordisk's dual-pathway combination — cagrilintide (long-acting amylin analog) co-formulated with semaglutide (GLP-1 RA) in a single weekly injection. Phase 3 data shows ~22.7% weight loss, competitive with tirzepatide. This is the amylin pathway's answer to GIP.
Two pathways. Redundant suppression.
CagriSema's innovation isn't a new receptor — it's pharmacological redundancy. By targeting both GLP-1 and amylin pathways simultaneously, appetite suppression is maintained even if one pathway partially adapts. Amylin also suppresses glucagon through a mechanism distinct from GLP-1.
Follows the semaglutide playbook.
As a co-formulation, CagriSema's titration mirrors semaglutide-style escalation with both components increasing in parallel in a single pre-filled injection.
The REDEFINE program — Novo Nordisk's next play.
The REDEFINE trials (Phase 3) represent Novo Nordisk's response to Eli Lilly's tirzepatide. Early data shows approximately 22.7% weight loss — competitive with tirzepatide and approaching retatrutide territory. The amylin pathway offers genuinely different biology from GIP, giving the obesity landscape real mechanistic diversity.
CagriSema's advantage is that both components have extensive individual safety data. Semaglutide is the most-studied GLP-1, and amylin analogs (pramlintide/Symlin) have been FDA-approved since 2005. The combination is pharmacologically conservative even as it pushes efficacy boundaries.
How it stacks against the competition.
| Compound | Receptors | Weight Loss | Half-Life | FDA Status |
|---|---|---|---|---|
| Semaglutide | GLP-1 | ~15–17% | ~7 days | Approved (Wegovy) |
| Tirzepatide | GLP-1 + GIP | ~20–26% | ~5 days | Approved (Zepbound) |
| CagriSema | GLP-1 + Amylin | ~22.7% | ~7 days | Phase 3 Trial |
| Retatrutide | GLP-1 + GIP + GCGR | ~24% | ~6 days | Phase 3 Trial |
| Survodutide | GLP-1 + GCGR | ~19% | ~4 days | Phase 3 Trial |
What to watch for.
CagriSema's side effect profile requires careful monitoring. GI effects are expected to mirror high-dose semaglutide, with cagrilintide potentially adding injection site reactions.
- GI effects consistent with GLP-1 class (nausea, diarrhea, constipation)
- Injection site reactions (cagrilintide may add local reactions)
- Decreased appetite (therapeutic effect)
- Vomiting (primarily during titration)
- Safety profile expected similar to high-dose semaglutide
- Long-term data still accumulating
- HbA1c and fasting glucose
- Fasting insulin
- Complete lipid panel
- Thyroid panel
- Liver enzymes (ALT, AST)
- Kidney function
- Pancreatic enzymes (amylase, lipase)
- CMP baseline
- Co-formulated product — not typically stacked with additional GLP-1 compounds
- High protein diet (1g/lb) + resistance training for muscle preservation
- BPC-157 for GI support if needed
- CJC-1295/Ipamorelin for lean mass protection
- DO NOT add additional GLP-1 or amylin agonists
- Limited research-grade availability — extreme caution with vendors
- Pharmaceutical guidelines when approved
- Research: refrigerate at 2–8°C
- Limited research-grade availability
- Extreme caution with claimed CagriSema from vendors
- Co-formulation complex — verify both components on COA
- Novo Nordisk pharmaceutical grade preferred
Compounds that complement CagriSema.
CagriSema is co-formulated, so stacking focuses on GI support, muscle preservation, and non-overlapping metabolic pathways. Do not add additional GLP-1 or amylin compounds.
The pharmacologically conservative powerhouse.
CagriSema represents the smart play from Novo Nordisk — combining proven semaglutide with well-characterized amylin pathway. Both components have individual clinical histories. The result competes with tirzepatide on efficacy while building on a deeper safety foundation. Not yet approved, research-grade availability is extremely limited, and quality control on claimed CagriSema from vendors is questionable. Wait for pharmaceutical approval or proceed with extreme caution and full medical oversight.
Our free 50-page Protocol Guide includes the complete Metabolic Fat Loss Stack with CagriSema — titration schedules, stacking recommendations, blood work panels, and tracking templates.